Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Billingsley, Robert
NCT04092686 / 2019-000697-37: A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia	Completed	3	464	Europe, US, RoW	SEP-363856 75mg, SEP-363856 100mg, Placebo	Otsuka Pharmaceutical Development & Commercialization, Inc., Sunovion Pharmaceuticals Inc.	Schizophrenia	06/23	06/23
NCT06179108: Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia	Active, not recruiting	2	350	US	LB-102	LB Pharmaceuticals Inc.	Schizophrenia	12/24	05/25
NCT05848700: A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia	Completed	1	60	US	SEP-363856, Placebo	Otsuka Pharmaceutical Development & Commercialization, Inc.	Schizophrenia	03/24	03/24